APRIL-based chimeric antigen receptor (CAR) T cells, which recognize both BCMA and TACI, have been developed and found to be effective in killing MM cells and providing tumor regression, even at very low BCMA and TACI densities [217]. This evidence concerns the gene TNFSF13 and Miyoshi myopathy.